Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2018 05:26 ET | Source: Genmab A/S

Genmab Announces European Commission Approval of DARZALEX® (daratumumab) Split Dosing Regimen

Media Release Split dosing regimen approved by European CommissionProvides healthcare professionals with option to split first DARZALEX infusion over two consecutive daysApproval supported by data...
December 13, 2018 20:58 ET | Source: Genmab A/S

Genmab Announces Submission of Supplemental New Drug Application for Daratumumab in Front Line Multiple Myeloma in Japan

Company Announcement Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed...
December 10, 2018 13:41 ET | Source: Genmab A/S

Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab

Company Announcement Copenhagen, Denmark; December 10, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 80,380 restricted stock units to...
December 03, 2018 02:17 ET | Source: Genmab A/S

Genmab to Hold R&D Update and 2018 ASH Data Review Meeting

Media Release Event to be held today in San Diego, CaliforniaIndependent experts to discuss data presented at the 2018 ASH Annual MeetingMeeting to be webcast live and archived on www.genmab.com ...
November 26, 2018 08:30 ET | Source: Genmab A/S

Genmab to Hold R&D Update and 2018 ASH Data Review Meeting

Media Release Event to be held live in San Diego, CaliforniaIndependent experts to discuss data presented at the 2018 ASH Annual MeetingMeeting to be webcast live and archived on www.genmab.com ...
November 20, 2018 12:20 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; November 20, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 7,588 shares as a consequence of the exercise of employee...
November 20, 2018 09:07 ET | Source: Genmab A/S

Data from Phase III MAIA Study of Daratumumab Accepted for Presentation at Annual Meeting of American Society of Hematology

Media Release Data from Phase III MAIA study in front line multiple myeloma accepted as Late-breaking Abstract for oral presentation at ASH Annual Meeting Copenhagen, Denmark; November 20, 2018 –...
November 19, 2018 07:21 ET | Source: Genmab A/S

CHMP Issues Positive Opinion on Split Dosing Regimen for DARZALEX® (daratumumab)

Media Release CHMP issued positive opinion on split dosing regimen for DARZALEX Final decision from European Commission expected in the coming monthsOpinion supported by data from EQUULEUS...
November 14, 2018 11:00 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2018

November 14, 2018; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2018 Highlights USD 1,441 million in net sales of DARZALEX® (daratumumab), resulting in royalty...
November 08, 2018 08:57 ET | Source: Genmab A/S

Genmab to Present at the Jefferies 2018 London Healthcare Conference

Media Release Copenhagen, Denmark; November 8, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the company’s CEO, Jan van de Winkel, Ph.D., will present an update at the Jefferies 2018...